Anecortave Acetate Versus Placebo in AMD Patients Following PDT
The purpose of this study was to evaluate the efficacy of anecortave acetate for depot suspension (30 mg and 15 mg) plus PDT versus PDT alone with respect to maintenance of visual acuity in patients with wet AMD.
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Anecortave Acetate Versus Placebo in AMD Patients Following PDT|
- Mean change from the baseline in logMAR visual acuity score at Month 6
- % patients who maintained vision, number of months of angiographic evidence of needing PDT re-treatment, and mean lesion sizes for the total choroidal neovascularization (CNV) and the classic component to the total CNV.
|Study Start Date:||May 2000|
|Study Completion Date:||December 2001|
|Primary Completion Date:||December 2001 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00346866
|United States, Ohio|
|Beachwood, Ohio, United States, 44122|
|Study Director:||Patricia Zilliox||Alcon Research|